Technology Innovation Institute Appoints Globally-Renowned Experts to Board of Advisors at Autonomous Robotics Research Centre
7.4.2021 13:30:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of leading international experts to the Board of Advisors at its Autonomous Robotics Research Centre (ARRC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005504/en/
Dr. Najwa Aaraj, Acting Chief Researcher at Autonomous Robotics Research Centre (Photo: AETOSWire)
The appointments follow a series of rapid announcements at Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020.
Autonomous Robotics Research Centre is one of the initial seven specialised centres at the Technology Innovation Institute. Members of the new Board of Advisors are renowned experts in various fields of intelligent autonomy, autonomous systems and robotics, robotics and perception, among others. The Centre’s researchers are engaged in exploring the latest advances in robotics that will help build hybrid societies made up of biological and artificial systems. The distinguished Board of Advisors will guide efforts to develop breakthrough technologies that have global impact.
The Board of Advisors includes Prof. Ian F. Akyildiz, the Ken Byers Chair Professor, Director of the Broadband Wireless Networking Lab and Chair of the Telecommunications Group at the School of Electrical and Computer Engineering at the Georgia Institute of Technology in the United States; Prof. Luca Benini, Chair of Digital Circuits and Systems at the Department of Information Technology and Electrical Engineering of the Swiss Federal Institute of Technology (ETH) Zurich and Professor of Electronics at Italy’s University of Bologna; Prof. Marko Bertogna, Professor at the University of Modena and Reggio Emilia in Italy, where he leads the High-Performance Real-Time Systems Laboratory; Prof. A. E. Eiben, Professor of Artificial Intelligence (AI) and Collective Systems at the Vrije Universiteit Amsterdam in the Netherlands and Visiting Professor at the University of York in the UK; Prof. Giuseppe Loianno, Assistant Professor of Robotics and Perception at New York University in the United States, and Prof. Martin Saska, founder of the Multi-Robot Systems Group at the Department of Cybernetics of Czech Technical University in Prague.
Speaking about the new appointments, Dr Najwa Aaraj, Acting Chief Researcher at Autonomous Robotics Research Centre, said: “The board members will facilitate scientific collaborations that will enable verifiable, rigorous, systematic, and empirical scientific investigation and research in advanced technology, putting Abu Dhabi and the wider UAE in a prime position to shape future capabilities in autonomous robotics across all dimensions - air, land, water, underwater, and even in space.”
About Technology Innovation Institute (TII):
Technology Innovation Institute (TII) is the dedicated ‘applied research’ pillar of Advanced Technology Research Council (ATRC). TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation.
For more information, visit www.tii.ae
About Autonomous Robotics Research Centre (ARRC):
Autonomous Robotics Research Centre (ARRC) – at Technology Innovation Institute (TII) – is dedicated to breakthrough developments in robotics and autonomy. With in-depth technical expertise in robotics, computer vision, and bio-inspired technologies, the Centre has established a leadership position in its field.
For more information, visit https://autonomousrobotics.tii.ae/
Connect with us on social media:
LinkedIn: https://www.linkedin.com/company/tiiuae/
Twitter: https://twitter.com/TIIuae
Instagram: https://www.instagram.com/tiiuae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005504/en/
Contact information
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom